Progression-free survival 3 of 22 months achieved through third-line therapy with adebrelimab in patient with recurrent chordoma: a case report.
Saved in:
| Title: | Progression-free survival 3 of 22 months achieved through third-line therapy with adebrelimab in patient with recurrent chordoma: a case report. |
|---|---|
| Authors: | Sun L; Department of Pathology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.; School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China., Lang J; Department of Pathology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.; School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China., Zhang W; Department of Pathology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.; School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China., Xiong Z; School of Medicine, Shaoxing University, Shaoxing, Zhejiang, China.; Department of Radiation Oncology, Shaoxing Second Hospital, Shaoxing, Zhejiang, China. |
| Source: | Frontiers in oncology [Front Oncol] 2026 Jun 29; Vol. 16, pp. 1850680. Date of Electronic Publication: 2026 Jun 29 (Print Publication: 2026). |
| Publication Type: | Case Reports; Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2026.1850680 |
